Gynecologic Oncology Reports最新文献_第9页

Quality and accuracy of physician and chatbot responses to clinical questions in gynecologic oncology: Correspondence 妇科肿瘤学中医生和聊天机器人对临床问题反应的质量和准确性：对应

IF 1.2

Gynecologic Oncology Reports Pub Date : 2025-04-01 DOI: 10.1016/j.gore.2024.101507

Hinpetch Daungsupawong , Viroj Wiwanitkit

引用次数: 0

Placement of delayed absorbable mesh to prevent herniation following left diaphragm peritonectomy during ovarian cancer cytoreduction 在卵巢癌细胞减少术中放置延迟可吸收补片以防止左膈腹膜切除术后疝

IF 1.2

Gynecologic Oncology Reports Pub Date : 2025-04-01 DOI: 10.1016/j.gore.2025.101703

Ryan M. Kahn , Dennis S. Chi

{"title":"Placement of delayed absorbable mesh to prevent herniation following left diaphragm peritonectomy during ovarian cancer cytoreduction","authors":"Ryan M. Kahn , Dennis S. Chi","doi":"10.1016/j.gore.2025.101703","DOIUrl":"10.1016/j.gore.2025.101703","url":null,"abstract":"<div><h3>Background</h3><div>In the management of advanced ovarian cancer, complex surgery is often necessary to achieve the goal of complete gross resection. Diaphragm resections and intrathoracic procedures are safe and feasible in select patients with advanced ovarian cancer. In our institution, up to 68% of cytoreductive surgery requires diaphragm peritonectomy, and 11% involve intrathoracic cytoreduction (<span><span>Kahn et al., 2023</span></span>, <span><span>Kahn et al., 2024</span></span>). The left diaphragm is often involved, requiring a peritonectomy. The most common complications include pleural effusion and pneumothorax, although a rare complication of left-sided diaphragmatic herniation has been reported (<span><span>Ehmann et al., 2021a</span></span>, <span><span>Ehmann et al., 2021b</span></span>).</div></div><div><h3>Methods</h3><div>With this video, our goal is to introduce the novel idea of placing delayed absorbable mesh to reduce the risk of left diaphragmatic herniation following left diaphragm peritonectomy, as well as demonstrate the surgical technique of polyglactin 910 mesh placement during cytoreductive surgery for ovarian cancer.</div></div><div><h3>Results</h3><div>We demonstrate a left diaphragm mesh placement during cytoreductive surgery for ovarian cancer, with the steps as follows: measure the diaphragmatic defect to the peritoneal edges with muscle fibers in-between and cut the mesh along the contour; suture in the right center and left center of mesh from the intraperitoneal side to the diaphragm side and then out to initially anchor to the diaphragm; continue to throw interrupted stitches circumferentially around the woven mesh beginning from the center and extending outwards.</div></div><div><h3>Conclusion</h3><div>Delayed absorbable mesh placement is a feasible technique that may help reduce the risk of left diaphragmatic herniation following peritonectomy in cytoreductive surgery for ovarian cancer.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"58 ","pages":"Article 101703"},"PeriodicalIF":1.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143834878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ovotesticular disorders of sex development with dysgerminoma in a 46, XX/46, XY female: A case report 46, XX/46， XY女性性发育障碍伴生殖细胞异常瘤1例

IF 1.2

Gynecologic Oncology Reports Pub Date : 2025-04-01 DOI: 10.1016/j.gore.2025.101735

Yafei Xue , Shuqi Zuo , Min Cui , Xingbo Zhao , Xiaoyi Qi

{"title":"Ovotesticular disorders of sex development with dysgerminoma in a 46, XX/46, XY female: A case report","authors":"Yafei Xue , Shuqi Zuo , Min Cui , Xingbo Zhao , Xiaoyi Qi","doi":"10.1016/j.gore.2025.101735","DOIUrl":"10.1016/j.gore.2025.101735","url":null,"abstract":"<div><div>The diagnosis of ovotesticular disorders of sex development can only be confirmed when both testicular and ovarian tissues are present simultaneously in the same individual, regardless of the patient’s karyotype. This report aims to discuss the diagnosis and treatment of a rare case of ovotesticular disorders of sex development complicated by dysgerminoma. The patient, a 24-year-old female, was admitted to hospital due to clitoral hypertrophy. Chromosomal analysis revealed a chimeric karyotype of 46, XX/46, XY. Biopsies of both ovaries indicated the presence of dysgerminoma in the right ovarian tissue. Postoperative pathology confirmed true hermaphroditism with dysgerminoma. Surgical intervention included the removal of the right ovary and plastic surgery of the external genitalia. Adult ovotesticular disorders of sex development combined with dysgerminoma is exceptionally rare, particularly with a chimeric karyotype. Comprehensive analysis of clinical manifestations, cytogenetic examination, histomorphology, and immunophenotype is crucial for accurate diagnosis and treatment. Early intervention and surgical management are essential to prevent disease progression.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"58 ","pages":"Article 101735"},"PeriodicalIF":1.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143791596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Management of high-grade ovarian adenocarcinoma in an intraperitoneal pelvic renal transplant recipient 一例盆腔内肾移植受者高级别卵巢腺癌的处理

IF 1.2

Gynecologic Oncology Reports Pub Date : 2025-04-01 DOI: 10.1016/j.gore.2025.101726

Hadi Erfani , Esra Demirel , Farr Nezhat

{"title":"Management of high-grade ovarian adenocarcinoma in an intraperitoneal pelvic renal transplant recipient","authors":"Hadi Erfani , Esra Demirel , Farr Nezhat","doi":"10.1016/j.gore.2025.101726","DOIUrl":"10.1016/j.gore.2025.101726","url":null,"abstract":"<div><h3>Background</h3><div>The increasing number of organ transplant recipients has led to a rise in cancer diagnoses in this population. Kidney transplant recipients, in particular, have a two-to-four-fold higher risk of developing cancer due to immunosuppressive therapy. The management of gynecologic cancers in this subset of patients presents unique challenges due to anatomical considerations, immunosuppression, and the nephrotoxicity of oncologic treatments.</div><div>Case Presentation.</div><div>A 44-year-old woman with a history of polycystic kidney disease underwent a bilateral nephrectomy followed by a living-related intraperitoneal renal transplant. She presented with pelvic pain and was found to have high-grade ovarian adenocarcinoma, possibly arising from endometriosis. Surgical staging included total laparoscopic hysterectomy, bilateral salpingo-oophorectomy, omentectomy, and right pelvic lymph node dissection. The patient underwent six cycles of carboplatin and paclitaxel chemotherapy while maintaining stable renal function with close monitoring of immunosuppressive drug levels. Surveillance imaging detected recurrence in the right pelvic lymph nodes, leading to secondary tumor debulking and whole pelvic radiation therapy. Despite a slight increase in creatinine, kidney function remained stable, and the patient has remained disease-free on subsequent follow-ups.</div></div><div><h3>Conclusion</h3><div>The management of ovarian cancer in kidney transplant recipients requires a multidisciplinary approach to balance oncologic control with graft preservation. Close monitoring of renal function, careful surgical planning, and tailored chemotherapy and radiation strategies are critical. More research is needed to establish standardized guidelines for managing gynecologic malignancies in transplant patients.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"58 ","pages":"Article 101726"},"PeriodicalIF":1.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143834879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Robotic vascular control of the vena cava for oligometastatic recurrent endometrial cancer 机器人控制腔静脉治疗少转移性复发子宫内膜癌

IF 1.2

Gynecologic Oncology Reports Pub Date : 2025-04-01 DOI: 10.1016/j.gore.2025.101702

Kaleigh Olmsted, Sydney Oesch, Justin Harold

引用次数: 0

Surgical education video: Bilateral radical vulvectomy with immediate pudendal thigh perforator flap reconstruction 手术教育录像：双侧根治性外阴切除术合并即刻阴部股穿支皮瓣重建

IF 1.2

Gynecologic Oncology Reports Pub Date : 2025-04-01 DOI: 10.1016/j.gore.2025.101696

Prachi Shah , Kathryn A Mills

引用次数: 0

Adnexal mass referral patterns in Gynecologic Oncology 妇科肿瘤学附件肿块转诊模式

IF 1.2

Gynecologic Oncology Reports Pub Date : 2025-03-25 DOI: 10.1016/j.gore.2025.101729

Rusha Bajpai, Tammy Mundale, Natalia Gontarczyk Uczkowski, Amy Godecker, Stephen Rose

{"title":"Adnexal mass referral patterns in Gynecologic Oncology","authors":"Rusha Bajpai, Tammy Mundale, Natalia Gontarczyk Uczkowski, Amy Godecker, Stephen Rose","doi":"10.1016/j.gore.2025.101729","DOIUrl":"10.1016/j.gore.2025.101729","url":null,"abstract":"<div><h3>Objectives</h3><div>There is a perceived increase in adnexal mass referrals to Gynecologic Oncology that do not meet American College of Obstetricians and Gynecologists (ACOG) referral criteria. There is little data regarding referral patterns to Gynecologic Oncology. Our primary objective is to determine the proportion of consults meeting ACOG referral criteria over an eleven year period.</div></div><div><h3>Methods</h3><div>A retrospective chart review was conducted for adnexal mass referrals between 2011 and 2021. Variables such as age, menopausal status, imaging findings, tumor markers, surgery and histopathologic diagnosis determined whether the initial consult met ACOG referral criteria.</div></div><div><h3>Results</h3><div>A total of 864 new consults were reviewed, 84.7 % meeting ACOG referral criteria. When broken down by year, 82.0 %, 78.9 %, 82.2 %, 86.1 %, 92.6 % met criteria for the years 2011, 2012, 2016, 2018, 2021, respectively. There was a significantly higher proportion of consults meeting referral criteria in 2021 compared to 2011 (p = 0.003). In 2011, 37.8 % of surgical cases meeting ACOG criteria were malignant compared to 45.2 % in 2021 (p = 0.145).</div></div><div><h3>Conclusions</h3><div>Our service has seen an increasing proportion of adnexal mass referrals that meet ACOG referral criteria. There is also a trending increase in malignant histopathology. This may be due to increased scrutiny of referrals by gynecologic oncologists starting in 2016 with appropriate referral to benign gynecology. Improved scrutiny of adnexal mass referrals could decrease the number of benign cases evaluated by Gynecologic Oncology, helping preserve resources for patients with higher risk of malignancy.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"58 ","pages":"Article 101729"},"PeriodicalIF":1.2,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143714788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Four-year recurrence-free survival in metastatic uterine adenosarcoma with somatic BRCA2 mutation on olaparib therapy: A case report 奥拉帕尼治疗伴有BRCA2体细胞突变的转移性子宫腺肉瘤四年无复发生存率：1例报告

IF 1.2

Gynecologic Oncology Reports Pub Date : 2025-03-19 DOI: 10.1016/j.gore.2025.101724

Katie Foug , Stephanie L. Skala , Erica Stien , Kevin Reynolds , Jean Siedel , Shitanshu Uppal

引用次数: 0

Surgical staging identifies occult metastases in over 50% of uterine-confined carcinosarcoma 手术分期发现超过50%的子宫局限性癌肉瘤存在隐匿性转移

IF 1.2

Gynecologic Oncology Reports Pub Date : 2025-03-18 DOI: 10.1016/j.gore.2025.101722

William Vintzileos, Hannah Beer, David Miller, Jayanthi Lea

{"title":"Surgical staging identifies occult metastases in over 50% of uterine-confined carcinosarcoma","authors":"William Vintzileos, Hannah Beer, David Miller, Jayanthi Lea","doi":"10.1016/j.gore.2025.101722","DOIUrl":"10.1016/j.gore.2025.101722","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate and define the proportion of clinically stage I Uterine Carcinosarcoma (UCS) patients who are upstaged to FIGO stages II-IVB following primary surgery based on final pathology.</div></div><div><h3>Methods</h3><div>We performed a retrospective review of patients diagnosed and treated for UCS at our institution from 2009 to 2023. All patients who underwent primary surgery for UCS and had clinically stage I (uterine-confined) disease were included. Uterine-confined disease was determined based on pre-operative physical exam and imaging. The primary outcome was the proportion of patients who were upstaged after surgery.</div></div><div><h3>Results</h3><div>Ninety-eight patients underwent primary surgery with a median age of 64 years (IQR 59–68). Twenty-six patients (26.6 %) had suspected extra-uterine disease based on pre-operative evaluation and were excluded. Seventy-two patients (73.4 %) had uterine-confined disease based on pre-operative exam/imaging and underwent staging surgery. Of the 72 patients with clinical stage I disease, 39 patients (54.2 %) were ultimately diagnosed with advanced disease (FIGO Stages II-IVB), while 33 patients (45.8 %) had confirmed early-stage disease on final pathology (FIGO Stages IA or IB). Surgical staging revealed the following: 15.4 % (n = 6) were upstaged to Stage II, 5.1 % (n = 2) to Stage IIIA, 5.1 % (n = 2) to Stage IIIB, 35.9 % (n = 14) to Stage IIIC1, 12.8 % (n = 5) Stage IIIC2, and 25 % (n = 10) to Stage IVB.</div></div><div><h3>Conclusion</h3><div>More than 50% of patients with pre-operative “uterine-confined” carcinosarcoma were upstaged on final pathology, mostly commonly to Stage III. Our findings underscore the importance of surgical staging since upstaging carries critical prognostic information and implications for adjuvant treatment planning.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"58 ","pages":"Article 101722"},"PeriodicalIF":1.2,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143654471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Triple synchronous primary cancers comprising large cell neuroendocrine carcinoma of the lower uterine segment and endometrioid carcinomas of the uterine corpus and the right ovary-a rare combination: A case report 包括下子宫段大细胞神经内分泌癌和子宫体及右侧卵巢子宫内膜样癌的三同步原发性癌——罕见的合并病例报告

IF 1.2

Gynecologic Oncology Reports Pub Date : 2025-03-16 DOI: 10.1016/j.gore.2025.101721

Kaichiro Yamamoto , Shin-ichi Nakatsuka , Tomochika Goto , Reiko Samoto , Aki Minami , Masatoshi Imamura

{"title":"Triple synchronous primary cancers comprising large cell neuroendocrine carcinoma of the lower uterine segment and endometrioid carcinomas of the uterine corpus and the right ovary-a rare combination: A case report","authors":"Kaichiro Yamamoto , Shin-ichi Nakatsuka , Tomochika Goto , Reiko Samoto , Aki Minami , Masatoshi Imamura","doi":"10.1016/j.gore.2025.101721","DOIUrl":"10.1016/j.gore.2025.101721","url":null,"abstract":"<div><div>We report a rare case of triple primary cancers in a 52-year-old woman who presented with abdominal pain and fever. Diagnostic imaging and subsequent histopathological evaluation revealed independent primary endometrioid carcinomas of the ovary and uterine corpus proper (UC), as well as large cell neuroendocrine carcinoma (LCNEC) originating from the lower uterine segment (LUS). Surgical resection was performed, followed by adjuvant chemotherapy (irinotecan and cisplatin). The patient demonstrated no recurrence at the 10-month follow-up.</div><div>This case highlights the importance of accurate pathological differentiation, as prognosis and treatment depend on distinguishing independent primary tumors from metastatic lesions. This rare case of triple synchronous malignancies emphasizes the need for a multidisciplinary approach to ensure precise diagnosis and optimal management. Comprehensive molecular studies and advanced imaging techniques may further improve outcomes in such complex cases.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"58 ","pages":"Article 101721"},"PeriodicalIF":1.2,"publicationDate":"2025-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143654470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0